insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Pharma & Biotech
Pharma & Biotech
Is insitro’s TherML platform finally delivering on the AI-native promise for biologics and small molecules?
insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical